Bacterial Antigen Ingredients TRIZ Cases

Measuring Th17 and Treg cell ratios in bladder biopsies predicts BCG therapy response, resolving uncertainty in treatment selection.

Engineered T cells expressing self-antigens overcome low engraftment rates by providing sustained antigen presentation for improved persistence.

Dual mutant protective antigens require distinct proteinases to form hetero-oligomers, reducing non-specific cytotoxicity while maintaining delivery efficiency.

Arabinose ester of mycolic acid antigens bind sample antibodies to detect biomarkers, resolving diagnostic reliability versus time trade-offs.

Mb3645c-derived peptides differentiate infected from vaccinated animals, resolving cross-reactivity issues inherent in PPD-based diagnostic assays.

Replacing ultracentrifugation with lytic enzymes and membrane filtration reduces process time while maintaining WHO-grade purity.

Artificial multi-antigen fusion protein stimulates CD8+ and CD4+ T cell immunity via cathepsin cleavage sites.

Alginate microsphere encapsulation controls the release rate of attenuated Brucella strains, preventing splenomegaly while maintaining long-term immunity.

Engineered vaccine vector expressing conserved PAL polypeptides on its surface to elicit robust immune responses against diverse gram-negative bacteria.

Extracting the EtpE-C protein resolves diagnostic accuracy gaps by enabling early detection of Ehrlichia infections.

PeptiBAC platform uses poly-lysine linkers to coat BCG bacteria with targeted antigens, overcoming variable vaccine efficacy in adults and HIV patients.

Negatively charged immune-modifying particles alter myeloid-derived suppressor cells and tumor-associated macrophages.

A site-specific antibody-drug conjugate uses a controlled linker to ensure uniform drug loading and structural stability.

Lactobacillus fermentum strains inhibit lipase activity and triglyceride accumulation to address side effects from conventional obesity treatments.

A TagF-like capsule polymerase combines glycosyltransferase and hexose-phosphate transferase activities to synthesize polysaccharides with dimeric repeating units.

Lipid A-SAEP complexes incorporate carrier antigens to bypass the lag-phase and boost immunity.

Hypermethylated PCR products inhibit NlaIII restriction enzyme activity, enabling stable genetic modification of Neisseria lactamica for meningococcal vaccines.

Modified host cells produce high-yield bioconjugates by relaxing enzyme specificity to overcome low affinity limitations.

Bordetella pertussis-derived TLR2 agonists resolve waning immunity by driving protective Th1 and Th17 responses.

Engineered bacterial biofilms conjugate heterologous molecules to exopolysaccharide-associated proteins for targeted surface delivery.

Antibody-CdtB conjugates target lymphocytes to arrest cells at the G2 phase, resolving dosage control issues from high cellular sensitivity.

Nucleic acids encoding Bacillus thuringiensis polypeptides express pesticidal proteins in transformed plants.

Mrp polypeptide fusion vaccines resolve type-specific immunity limits by inducing cross-opsonic antibodies that kill divergent GAS and SDSE strains.

Segmentation of the NetB toxin isolates immunogenic regions from toxic domains, reducing toxicity while maintaining vaccine effectiveness.

Segmented T-cell cytokine profiles differentiate active from latent mycobacterial infections without direct bacterial culture.

Immunogenic composition uses squalene emulsion adjuvant to enhance neutralizing antibody production against C. difficile toxins.

Chimeric proteins derived from OmpT and Hes antigens overcome narrow serotype coverage by inducing broad protection across diverse STEC strains.

Composite pH-responsive and mucoadhesive polymer layers shield microbes from gastric acidity to enable precise intestinal release.

Genetically engineered mycobacterium mutants with inactivated global gene regulators reduce bacterial shedding and enable infected animal differentiation.

Antigen compositions overcome antibiotic resistance by expanding T-cells ex vivo, replacing complex multi-drug regimens with targeted immunotherapy.

PNP inhibitors elevate endogenous adjuvant levels to overcome weak subunit vaccine immunity.

Sialic acid coating on modified bacterial strains resists immune clearance, enabling enhanced tumor colonization and antitumor activity.

Irradiating pathogenic microorganisms with 0.5 to 2 kGy doses induces stable nucleotide insertions and deletions.

A monovalent cholera vaccine formulation using a live attenuated strain maintains stability at room temperature.

Edible vaccine composition immunizes insects against microbial pathogens using heat-killed bacterial antigens.

Bifidobacterium breve and bifidum degrade gluten peptides, repairing intestinal permeability without strict dietary restrictions.

A therapeutic vaccine alters cancer cell immunogenic profiles using Mycobacterium w to stimulate broad immune responses.

A viral vector coated with polypeptides re-engages pre-existing CD4+ memory T cells to enhance anti-tumor immune responses.